Literature DB >> 35648465

Recommendations for outcome measurement for deprescribing intervention studies.

Elizabeth A Bayliss1,2, Kathleen Albers1, Kathy Gleason1, Lisa E Pieper1, Cynthia M Boyd3, Noll L Campbell4,5, Kristine E Ensrud6,7, Shelly L Gray8, Amy M Linsky9,10, Derelie Mangin11,12, Lillian Min13,14, Michael W Rich15, Michael A Steinman16,17, Justin Turner18, Eduard E Vasilevskis19,20, Sascha Dublin21,22.   

Abstract

Interpreting results from deprescribing interventions to generate actionable evidence is challenging owing to inconsistent and heterogeneous outcome definitions between studies. We sought to characterize deprescribing intervention outcomes and recommend approaches to measure outcomes for future studies. A scoping literature review focused on deprescribing interventions for polypharmacy and informed a series of expert panel discussions and recommendations. Twelve experts in deprescribing research, policy, and clinical practice interventions participating in the Measures Workgroup of the US Deprescribing Research Network sought to characterize deprescribing outcomes and recommend approaches to measure outcomes for future studies. The scoping review identified 125 papers reflecting 107 deprescribing studies. Common outcomes included medication discontinuation, medication appropriateness, and a broad range of clinical outcomes potentially resulting from medication reduction. Panel recommendations included clearly defining clinically meaningful medication outcomes (e.g., number of chronic medications, dose reductions), ensuring adequate sample size and follow-up time to capture clinical outcomes resulting from medication discontinuation (e.g., quality of life [QOL]), and selecting appropriate and feasible data sources. A new conceptual model illustrates how downstream clinical outcomes (e.g., reduction in falls) should be interpreted in the context of initial changes in medication measures (e.g., reduction in mean total medications). Areas needing further development include implementation outcomes specific to deprescribing interventions and measures of adverse drug withdrawal events. Generating evidence to guide deprescribing is essential to address patient, caregiver, and clinician concerns about the benefits and harms of medication discontinuation. This article provides recommendations and an initial conceptual framework for selecting and applying appropriate intervention outcomes to support deprescribing research.
© 2022 The American Geriatrics Society.

Entities:  

Keywords:  deprescription; outcome assessment; polypharmacy

Mesh:

Year:  2022        PMID: 35648465      PMCID: PMC9489620          DOI: 10.1111/jgs.17894

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   7.538


  49 in total

1.  Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions.

Authors:  Ariel R Green; Patricia Lee; Emily Reeve; Jennifer L Wolff; Chi Chiung Grace Chen; Rachel Kruzan; Cynthia M Boyd
Journal:  J Am Board Fam Med       Date:  2019 May-Jun       Impact factor: 2.657

2.  Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2012-09-19       Impact factor: 5.562

3.  The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community.

Authors:  D Saliba; M Elliott; L Z Rubenstein; D H Solomon; R T Young; C J Kamberg; C Roth; C H MacLean; P G Shekelle; E M Sloss; N S Wenger
Journal:  J Am Geriatr Soc       Date:  2001-12       Impact factor: 5.562

4.  Potential overtreatment of diabetes mellitus in older adults with tight glycemic control.

Authors:  Kasia J Lipska; Joseph S Ross; Yinghui Miao; Nilay D Shah; Sei J Lee; Michael A Steinman
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

5.  Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes.

Authors:  Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur
Journal:  J Clin Epidemiol       Date:  2012-06-27       Impact factor: 6.437

6.  Development and validation of the medication regimen complexity index.

Authors:  Johnson George; Yee-Teng Phun; Michael J Bailey; David C M Kong; Kay Stewart
Journal:  Ann Pharmacother       Date:  2004-07-20       Impact factor: 3.154

7.  Deprescribing Medications for Chronic Diseases Management in Primary Care Settings: A Systematic Review of Randomized Controlled Trials.

Authors:  Hannah Dills; Kruti Shah; Barbara Messinger-Rapport; Kevin Bradford; Quratulain Syed
Journal:  J Am Med Dir Assoc       Date:  2018-08-11       Impact factor: 4.669

Review 8.  Patient-experienced burden of treatment in patients with multimorbidity - A systematic review of qualitative data.

Authors:  Michael Rosbach; John Sahl Andersen
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

9.  Identification of behaviour change techniques in deprescribing interventions: a systematic review and meta-analysis.

Authors:  Christina R Hansen; Denis O'Mahony; Patricia M Kearney; Laura J Sahm; Shane Cullinan; C J A Huibers; Stefanie Thevelin; Anne W S Rutjes; Wilma Knol; Sven Streit; Stephen Byrne
Journal:  Br J Clin Pharmacol       Date:  2018-09-22       Impact factor: 4.335

Review 10.  Making patient values visible in healthcare: a systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity.

Authors:  Dee Mangin; Gaibrie Stephen; Verdah Bismah; Cathy Risdon
Journal:  BMJ Open       Date:  2016-06-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.